- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05171270
AsseSSing Impact in pSoriatic Treatment (ASSIST)
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves trial and error to find the right medication for the right person. Very little is known about the decisions made to increase treatment in individual patients. Previous research in rheumatoid arthritis found that clinical measures of disease activity, patient reported outcomes and characteristics of the treating doctor all influenced the decision to change therapy in routine practice.
This investigators particularly want to establish whether routine use of the psoriatic arthritis impact of disease (PsAID-12) questionnaire in the clinic setting can enable a better understanding of the impact of PsA on each individual, improve physician-patient communication and lead to appropriate interventions. The PsAID-12 questionnaire is a relatively new European developed questionnaire measuring patient impact across 12 different domains in PsA.
This study will use routine implementation of the PsAID-12 questionnaire and see if this is related to treatment decisions and patient satisfaction. The investigators will also examine other factors that may influence treatment decisions including patient characteristics, physician characteristics, disease activity and quality of patient-physician interactions.
Studie Overzicht
Gedetailleerde beschrijving
This is an observational, cross-sectional study addressing the factors influencing treatment decisions in patients with PsA. Participants will be treated as usual in their routine clinical practice, but decisions on treatment will be recorded - whether treatment is escalated, unchanged or reduced, and why.
The study will be conducted in 25 rheumatology centres in Europe (UK, France, Germany, Spain and Italy) with five centres in each country. Each participant will only attend for one single study visit which is likely to last around 30 minutes in total. This will be alongside the participant's routine clinic visit. The PsAID-12 questionnaire will be implemented on a tablet computer but the remaining outcomes will be collected on paper CRFs and transferred to a database for analysis.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studiecontact
- Naam: Laura C Coates, MBChB
- Telefoonnummer: 07870257823
- E-mail: laura.coates@ndorms.ox.ac.uk
Studie Contact Back-up
- Naam: Jaia Barratt
- Telefoonnummer: 02031922074
- E-mail: assist@springer.com
Studie Locaties
-
-
-
Bamberg, Duitsland
- Werving
- Klinikum Bamburg
-
Contact:
- Axel Hueber
-
Berlin, Duitsland
- Werving
- Rheumatologische Schwerpunktpraxis
-
Contact:
- Jan Brandt-Jurgens
-
Frankfurt, Duitsland
- Werving
- Universitätsklinik Frankfurt
-
Contact:
- Michaela Kohm
-
Herne, Duitsland
- Werving
- Universitätsklinikum der Ruhr-Universität Bochum
-
Contact:
- Uta Kiltz
- E-mail: uta.kiltz@elisabethgruppe.de
-
Planegg, Duitsland
- Werving
- MVZ für Rheumatologie Dr. Martin Welcker GmbH
-
Contact:
- Martin Welcker
-
-
-
-
-
Clermont-Ferrand, Frankrijk, 63000
- Werving
- CHU Gabriel-Montpied
-
Contact:
- Martin Soubrier
- E-mail: msoubrier@chu-clermontferrand.fr
-
Le Mans, Frankrijk
- Werving
- Centre Hospitalier Le Mans
-
Contact:
- Emmanuelle Dernis
- E-mail: edernis@ch-lemans.fr
-
Marseille, Frankrijk
- Werving
- Hôpitaux Universitaires de Marseille
-
Contact:
- Sandrine Guis
- E-mail: sandrine.guis@ap-hm.fr
-
Paris, Frankrijk, 75651
- Werving
- GERPAL, Hopital de la Pitie
-
Contact:
- Laure Gossec
- E-mail: laura.gossec@aphp.fr
-
Toulouse, Frankrijk
- Werving
- Centre hospitalier universitaire (CHU) de Toulouse
-
Contact:
- Adeline Ruyssen-Witrand
- E-mail: ruyssen-witrand.a@chu-toulouse.fr
-
-
-
-
-
Campobasso, Italië
- Werving
- Ospedale Regionale Cardarelli
-
Contact:
- Ennio Lubrano
- E-mail: enniolubrano@hotmail.com
-
-
-
-
-
Barcelona, Spanje
- Nog niet aan het werven
- Hospital Clinic (Barcelona)
-
Contact:
- Julio Ramiez Garcia
- E-mail: julramga@gmail.com
-
Coruña, Spanje
- Nog niet aan het werven
- Complejo Universitario de a Coruña
-
Contact:
- Jose Antonio Pinto
- E-mail: jose.antonio.pinto.tasende@sergas.es
-
Madrid, Spanje
- Nog niet aan het werven
- Hospital Universitario 12 de octubre
-
Contact:
- Beatriz Joven Ibanez
- E-mail: beatrizjoven@hotmail.com
-
Oviedo, Spanje
- Nog niet aan het werven
- Hospital Universitario Central de Asturias
-
Contact:
- Ruben Queiro
- E-mail: rubenque7@yahoo.es
-
Salamanca, Spanje
- Werving
- Hospital Universitario de Salamanca
-
Contact:
- Carlos Montilla Morales
- E-mail: montillamorales.carlos@gmail.com
-
-
-
-
Greater Manchester
-
Manchester, Greater Manchester, Verenigd Koninkrijk, M13 9WL
- Werving
- Manchester University NHS Foundation Trust
-
Contact:
- Pauline Ho
- E-mail: pauline.ho@mft.nhs.uk
-
-
Oxfordshire
-
Oxford, Oxfordshire, Verenigd Koninkrijk, OX39DU
- Werving
- Oxford University Hospital NHS Foundation Trust
-
Contact:
- Laura C Coates, MBChB
- Telefoonnummer: 07870257823
- E-mail: laura.coates@ndorms.ox.ac.uk
-
-
Staffordshire
-
Stafford, Staffordshire, Verenigd Koninkrijk, ST16 3SR
- Nog niet aan het werven
- Midlands Partnership NHS Foundation Trust
-
Contact:
- Jon Packham
- E-mail: jon.packham@mpft.nhs.uk
-
-
Wales
-
Cardiff, Wales, Verenigd Koninkrijk, CF14 4HH
- Werving
- Cardiff and vale University LHB
-
Contact:
- Ernest Choy
- E-mail: choyEH@cardiff.ac.uk
-
-
Yorkshire
-
Bradford, Yorkshire, Verenigd Koninkrijk, BD9 6RJ
- Werving
- Bradford Teaching Hospitals NHS Foundation Trust
-
Contact:
- Sarah Twigg
- E-mail: sarah.twigg@bthft.nhs.uk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study and complete questionnaires in the local language.
- Aged 18 years or above.
- Diagnosed with PsA according to the ClASification of Psoriatic ARthritis (CASPAR) criteria and diagnosis confirmed by a rheumatologist (Taylor 2006).
Exclusion Criteria:
- Patients who don't speak or read the local language
- Patients who are not comfortable filling in an app-based questionnaire or paper CRF.
- Patients with a new diagnosis of PsA at the current clinic visit
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
Psoriatic arthritis
Psoriatic arthritis Impact of Disease questionnaires (PsAID) used within routine clinic consultation.
|
PsAID questionnaire
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Proportion of patients undergoing treatment escalation
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Treatment escalation definition includes increase in dose, frequency, change of route, new medication
|
During the consultation (cross sectional study so only one timepoint)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Reduction of therapy
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Treatment reduction definition includes decrease in dose, frequency, change in route, stopping medication
|
During the consultation (cross sectional study so only one timepoint)
|
PsAID-12 scores
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
PsA impact of disease score (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
CollaboRATE score
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Patient satisfaction with consultation (scale 0-9 where higher score is better)
|
During the consultation (cross sectional study so only one timepoint)
|
Perceived efficacy on Patient-physician interaction score (PEPPI)
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Perceived efficacy in consultation (scale 5-25 where higher score is better)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how much arthritis is driving treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how PsAID 12 influenced treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Likert scale 1-5 (scale 0-5 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how much enthesitis is driving treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how much psoriasis is driving treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how much systemic inflammation marker (CRP) is driving treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Physicians opinion of how much PROs are driving treatment decision
Tijdsspanne: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 287039
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Psoriatische arthritis
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk